- Home
- IMRX vs FENC Comparison
IMRX vs FENC Comparison
Compare IMRX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMRX | FENC |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.9M | 258.5M |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | IMRX | FENC |
|---|---|---|
| Price | $5.78 | $7.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $17.20 | $13.50 |
| AVG Volume (30 Days) | ★ 835.3K | 219.0K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $4.68 |
| 52 Week High | $10.08 | $9.92 |
Technical Indicators
Market Signals| Indicator | IMRX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 52.12 |
| Support Level | $5.93 | $7.35 |
| Resistance Level | $6.54 | $7.74 |
| Average True Range (ATR) | 0.38 | 0.36 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 0.51 | 70.00 |
Price Performance
Historical ComparisonAbout IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.